Meige disease: striatal dopaminergic preponderance

Area of Science:

• Neurology
• Pharmacology
• Movement Disorders

Background:

• Meige disease (blepharospasm and oromandibular dystonia) is a neurological movement disorder.
• The underlying pathophysiology is thought to involve basal ganglia dysfunction, potentially with dopamine preponderance.
• Understanding pharmacological responses can aid in diagnosis and treatment.

Purpose of the Study:

• To evaluate the effects of a dopamine agonist (apomorphine) and a cholinomimetic drug (physostigmine) on Meige disease symptoms.
• To compare these effects with haloperidol and levodopa.
• To explore the potential pharmacological distinction between Meige disease and tardive dyskinesia.

Main Methods:

• Five patients with Meige disease were administered apomorphine, physostigmine, haloperidol, and levodopa.
• Placebo injections were used as a control.
• Clinical assessments of facial dyskinesias were performed after each administration.

Main Results:

• Apomorphine significantly lessened facial dyskinesias in all patients.
• Physostigmine aggravated the facial dyskinesias.
• Haloperidol attenuated the facial dystonia, while levodopa showed no consistent effect. Placebo had no significant effect.

Conclusions:

• The findings support a hypothesis of striatal dopamine preponderance in Meige disease.
• The pronounced cholinergic aggravation of symptoms may differentiate Meige disease from tardive dyskinesia.
• Pharmacological profiling offers practical therapeutic implications for managing dystonic disorders.